FeesSafety
Pluang+

Diodes Inc rated Buy with $100.27 target, signaling 16.7% upside from current price.

Analyst Insights
13 Nov 2026, 11:07 WIB
Seeking Alpha
View Source
Bullish
Diodes Inc rated Buy with $100.27 target, signaling 16.7% upside from current price.

Analyst Jared Tan rates Diodes Incorporated as a Buy with a target price of $100.27, implying a 16.7% upside from its recent close of $85.89. Despite a sector-wide price decline, Diodes shows positive stock-specific performance after adjusting for market risk. Earnings per share estimates have increased by 38.6%, while the price-to-earnings ratio dropped from 23.2 to 14.3, indicating improved valuation. The analyst's base case EPS forecast is below consensus but still exceeds the company's cost of equity, supporting the Buy rating.

Diodes Incorporated is the subject of this report, with Pluang's Technology sector data providing market context as of Nov 13, 2026 16:21 WIB. Of 150 priced Technology-sector US stocks tradable on Pluang, 63 rose and 71 fell today. Notable movers include MSTR at USD 111.40 with a 1-day change of -2.63% and a Pluang order activity of 72% Sell / 28% Buy, NBIS at USD 125.60 with -2.62% change and 28% Sell / 72% Buy order activity, and AMD at USD 570.21 with -2.58% change and 54% Sell / 46% Buy order activity. The most notable figure is the 72% Sell order activity for MSTR.

More News

China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...

Bullish
1 hour ago
PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...

Company Fundamentals
Bullish
2 hours ago
Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...

Company Fundamentals
Neutral
2 hours ago
Shandong-South Korea Economic Conference opens with 23 new cooperation projects signed in Yantai.

Shandong-South Korea Economic Conference opens with 23 new cooperation projects signed in Yantai.

The 9th Shandong-South Korea Economic and Trade Cooperation Conference and Yantai South Korea Week began on November 6 in Yantai, Shandong Province, highlighting strong economic ties between Shandong and South Korea. Over 150 enterprises participated...

Bullish
4 hours ago
Magnite reports 20% revenue growth in Q3 2026, driven by connected TV and strong ad demand.

Magnite reports 20% revenue growth in Q3 2026, driven by connected TV and strong ad demand.

Magnite, the largest independent supply-side platform, posted a 20% year-over-year revenue increase and 46% adjusted EBITDA growth in Q3 2026, fueled by strong connected TV (CTV) growth and political advertising. Management expects CTV to grow over 2...

Market News
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App